Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5145920 | 0.73 | PLD1 (0.40) | HPGDRAB9ASMN1; SMN2CYP3A4KDM4E | |
| SCHEMBL1038366 | 0.71 | PRMT6 (0.50) | CYP3A4MAPTKDM4E | |
| SCHEMBL9550046 | 0.71 | KDM4E (0.31) | MAPTKDM4ELMNA | |
| Hydrochloric Acid SCHEMBL18281396 | 0.69 | KDM4E (0.34) | KDM4E | |
| SCHEMBL5668049 | 0.67 | SIGMAR1 (0.41) | CYP3A4MAPTSIGMAR1LMNAGAA | |
| SCHEMBL6369470 | 0.67 | HPGD (0.38) | HPGDNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL663152 | 0.67 | MAPT (0.35) | HPGDNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL16972826 | 0.66 | NOS3 (0.35) | — | |
| SCHEMBL3694032 | 0.66 | — | — | |
| SCHEMBL2049800 | 0.65 | MAPT (0.33) | HPGDNPC1RAB9ASMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0035474-B1 | AMIDINES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | claimed |
| CN-110452216-A | Anti-fibrosis pyridinone | INTERMUNE INC | 2019-11-15 | — | — | CN | disclosed |
| CN-106459042-B | Anti-fibrotic pyridinones | 英特穆恩公司 | 2019-06-28 | — | — | CN | disclosed |
| US-9616064-B2 | Rho kinase inhibitors and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| CN-106459042-A | Anti-fibrotic pyridinones | 英特穆恩公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-2763984-A1 | 1-PYRAZOLYL-3- (4- ( (2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- 1 - YL) UREAS AS P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2014-08-13 | — | — | EP | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2013050757-A1 | 1-PYRAZOLYL-3- (4- ( (2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- 1 - YL) UREAS AS P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2013-04-11 | — | — | WO | disclosed |
| WO-2012135697-A2 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-8173665-B2 | I-pheny 1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-08 | — | — | US | disclosed |
| US-5723610-A | Alcohol reactants for forming phenylpyrimidine derivatives and process for preparing said alcohols | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-03-03 | — | — | US | disclosed |
| US-5539115-A | FERROELECTRIC CRYSTALS FOR OPTICAL APPARATUS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-07-23 | — | — | US | disclosed |
| EP-0035474-B1 | AMIDINES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | ROCK1, ROCK2, RHOA | HPGD 1778/4885NPC1 2279/4885RAB9A 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.